News from medivir A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 10, 2019, 02:48 ET US National Cancer Institute Initiates Phase I Study of Treatment of Head and Neck Cancer Patients With Medivir's Birinapant and Radiation Therapy

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I study to investigate the safety and...


Aug 28, 2019, 02:43 ET Medivir AB - Interim Report January - June 2019

April – June Significant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The analysis shows...


Jun 13, 2019, 02:17 ET Selective Effect Signal on Liver Cancer Tissue in Phase Ia Study With MIV-818

Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) today announces the results of an analysis of data from the first six patients with advanced cancer in...


Jun 04, 2019, 02:42 ET Medivir to Present at the 2019 BIO International Convention

Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in Philadelphia, US. The...


Jun 03, 2019, 02:40 ET New Data From the Phase I Study of Birinapant in Combination With Keytruda® Presented at ASCO

Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®)...


May 27, 2019, 05:53 ET Medivir to Present at the Redeye Pre-ASCO Seminar on May 28

Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm. The presentation will...


May 16, 2019, 02:52 ET New Data From the Phase I Study of Birinapant in Combination With Keytruda® Will be Presented at the ASCO 2019

edivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®)...


May 13, 2019, 02:45 ET Positive Data From The Remetinostat Phase II Study in Basal Cell Carcinoma Presented at SID Annual meeting

Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of remetinostat...


May 09, 2019, 10:40 ET Resolutions at the Annual General Meeting in Medivir on 9 May 2019

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual...


May 07, 2019, 02:20 ET Data From the Remetinostat Phase II Study in Basal Cell Carcinoma Patients to be Presented at the 2019 SID Annual Meeting

Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat in basal...


May 06, 2019, 03:17 ET Safety and Efficacy Data From the MIV-711 Phase II Open Label Extension Study Presented at the OARSI World Congress

Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has been presented as a poster during the...


May 03, 2019, 02:54 ET Medivir AB - Interim Report, January - March 2019

anuary – March Significant events during the quarter The phase II study of birinapant in combination with Keytruda® in colorectal cancer patients...


Apr 30, 2019, 02:24 ET Data from the MIV-711 Phase II Program to be Presented at the OARSI World Congress

edivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis...


Apr 29, 2019, 02:18 ET Medivir Appoints New CFO

Medivir AB (Nasdaq Stockholm: MVIR) today announces the appointment of Magnus Christensen as new CFO of Medivir effective as of 12 August 2019. He...


Apr 10, 2019, 03:42 ET Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ) are hereby summoned to the annual general meeting on Thursday 9 May 2019 at 2 p.m. at the IVA's conference...


Apr 08, 2019, 06:37 ET Medivir's Annual Report for 2018 is Published

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2018 now is available at the company's website: www.medivir.com . 2018 ...


Mar 27, 2019, 03:48 ET The Nomination Committee´s Proposal for New Board of Directors to the Annual General Meeting 2019

Medivir AB (Nasdaq Stockholm: MVIR) today announces the Nomination Committee's proposal for a new Board of Directors to the Annual General Meeting...


Mar 12, 2019, 10:08 ET Medivir to Present at the Stockholm Corporate Finance Life Science Seminar on March 13

Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Stockholm Corporate Finance 11th Life Science Seminar in...


Feb 18, 2019, 02:51 ET Lotta Ferm Appointed as Interim CFO at Medivir

Medivir AB (Nasdaq Stockholm: MVIR) as previously announced, Erik Björk will leave the role as Medivir's CFO. Lotta Ferm will assume the role as...


Feb 14, 2019, 02:59 ET Medivir Ab - Year End Report, January - December 2018

Two new projects into clinic October – December Significant events during the quarter The first patient was dosed in the phase II study with...


Feb 07, 2019, 09:11 ET Medivir's Chief Financial Officer Erik Björk Leaves the Company

Medivir AB (Nasdaq Stockholm: MVIR) announces that the company's CFO, Erik Björk, has resigned today, February 7, 2019. Erik Björk, who took on the...


Dec 21, 2018, 02:42 ET First Patient With Colorectal Cancer Dosed in the Phase ll Study of Birinapant in Combination With Keytruda®

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient in the phase ll part of the BPT-201 study of birinapant in combination...


Dec 14, 2018, 03:00 ET The Transformation Into a Company Focused on Clinical Development of Pharmaceuticals has now been Completed and Medivir Gives a Project Update

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the transformation to focus the company's internal resources on its clinical development...


Nov 21, 2018, 02:48 ET Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies

Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid...


Oct 26, 2018, 02:56 ET Medivir AB - Interim Report January - September 2018

Increased focus where we can create the most value July – September Significant events during the quarter Positive top-line joint structure outcomes...